Evans Syndrome in Dogs — Treatment Protocol

What is Evans Syndrome?

• Immune-mediated hemolytic anemia (IMHA) — autoantibodies destroy red blood cells
• Immune-mediated thrombocytopenia (ITP/IMT) — autoantibodies destroy platelets

Diagnostic Criteria

Treatment Protocol

Phase 1 — Stabilization (Days 1–3)

• Strict cage rest (minimizes oxygen demand and trauma risk)
• IV catheter with minimal handling (thrombocytopenia = bruising/bleeding risk)
• Oxygen supplementation if PCV <15% or signs of respiratory distress
• IV fluids cautiously (avoid dilutional worsening of anemia)

• Indicated if PCV <12–15% or clinical signs of cardiovascular compromise
• pRBC (packed red blood cells) preferred over whole blood
• Cross-match if prior transfusion history
• Use with caution — transfusion reactions possible due to existing autoantibodies
• Pre-medicate: diphenhydramine 1–2 mg/kg IV or dexamethasone 0.1 mg/kg IV before transfusion

Phase 2 — Immunosuppression (First-Line)

• Dose: 2 mg/kg/day PO (or divided BID), or up to 2–4 mg/kg/day in severe cases
• Mechanism: Suppresses macrophage Fc-receptor-mediated erythrophagocytosis and platelet destruction; reduces autoantibody production
• Begin immediately once diagnosis confirmed
• In vomiting or obtunded patients: dexamethasone SP 0.3 mg/kg IV once daily as a bridge

• Dose: 2 mg/kg PO once daily for 2 weeks, then every other day (alternating with prednisolone)
• Onset: 2–4 weeks (slow-acting; not suitable as sole rescue agent)
• Monitor CBC for myelosuppression at 1–2 week intervals
• Avoid in cats (causes fatal myelosuppression); safe in dogs

Evans syndrome often warrants dual immunosuppression from the outset given its severity.

Phase 3 — Adjunctive and Second-Line Agents

• Dose: 0.5–1.0 g/kg IV over 6–12 hours (single dose)
• Mechanism: Saturates macrophage Fc receptors → slows destruction of antibody-coated RBCs and platelets
• Expensive but can produce rapid platelet increase within 24–48 hours
• Particularly useful when platelet count is dangerously low (<20,000/µL) and transfusion is needed

• Dose: 10–20 mg/kg PO BID (dogs)
• Increasingly preferred over azathioprine due to faster onset (~1–2 weeks) and lower bone marrow toxicity
• Can be used as a substitute or alongside prednisolone

• Dose: 5 mg/kg PO BID
• Useful in refractory cases; monitor blood levels if available
• GI side effects common; give with food

• Dose: 0.02 mg/kg IV (single dose; max 1 mg)
• Mechanism: Stimulates thrombopoiesis and "coats" platelets with drug to delay splenic destruction
• Particularly useful for rapidly boosting platelet count in acute severe ITP component
• Can repeat in 5–7 days if needed

• Dose: 5 mg/kg PO BID–TID
• Androgen with immunomodulatory effects; useful as a long-term adjunct
• Slow onset (weeks); best used in conjunction with other agents

Phase 4 — Refractory/Rescue Options

• Dose: 2–4 mg/kg PO once daily
• Useful adjunct especially in IMHA-dominant Evans syndrome

• Anti-CD20 monoclonal antibody; depletes B cells
• Dose extrapolated from human protocols; anecdotal reports in dogs
• Reserved for severe refractory cases

• Considered when medical management repeatedly fails
• Removes a major site of antibody production and RBC/platelet destruction
• Higher risk in thrombocytopenic patients (surgical bleeding risk); stabilize platelets first (target >50,000/µL before surgery)
• Post-splenectomy: continued immunosuppression required; monitor for infection

Anticoagulation — A Critical Consideration

• Consider low-dose aspirin (0.5 mg/kg PO once daily) or
• Clopidogrel (Plavix) 2–4 mg/kg PO once daily
• Unfractionated heparin 100–200 IU/kg SC TID or LMWH (dalteparin 100–150 IU/kg SC BID) if high thrombotic risk

Tapering Protocol

1. Reduce prednisolone by 25% every 4–6 weeks
2. Total immunosuppression duration: minimum 4–6 months, often 6–12 months
3. Azathioprine or MMF tapered slower than steroids
4. Monitor CBC monthly during tapering; bi-monthly once stable

Monitoring

Prognosis

• Guarded to poor — mortality higher than IMHA or ITP alone
• Reported survival rates: ~50–70% with aggressive treatment
• Relapse is common (30–40%); long-term or lifelong low-dose immunosuppression may be needed in some dogs
• Underlying triggers (neoplasia, tick-borne disease, drugs) must be identified and addressed, as secondary Evans syndrome carries a different prognosis